Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.

Human gene therapy - 1 Oct 1993

Liem S E, Ramezani A, Li X, Joshi S

Abstract excerpt

Trans-dominant mutants of human immunodeficiency virus type 1 (HIV-1) Tat and Rev are attractive candidates for use in gene therapy in the treatment of HIV-1 infections because both are essential for viral replication. Retroviral vectors were constructed to allow either Tat-inducible or Tat- and Rev-inducible expression of trans-dominant mutants of Tat and Rev. These vectors were used to infect a human CD4+...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Base Sequence
Share to Cell Line

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, Dominant

Share to Molecular Sequence Data

Share to Mutation

Share to RNA, Messenger

Source

Identifiers

PMID: 8280800
DOI: 10.1089/hum.1993.4.5-625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.PMID 8280800Read ↗

Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.Semantic proximity Read ↗

Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells.Semantic proximity Read ↗

Inhibition of HIV/SIV replication by dominant negative Gag mutants.Semantic proximity Read ↗

Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells.Semantic proximity Read ↗

A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.Semantic proximity Read ↗

Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.Semantic proximity Read ↗

A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection.Semantic proximity Read ↗

Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins.Semantic proximity Read ↗

Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape.Semantic proximity Read ↗

Construction and characterization of a potent HIV-2 Tat transdominant mutant protein.Semantic proximity Read ↗

Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.Semantic proximity Read ↗

Suppression of HIV replication by dominant negative mutants of HIV-1 (review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.